{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:52Z","timestamp":1740144052969,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40264-021-01083-x","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T03:37:00Z","timestamp":1622691420000},"page":"825-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper"],"prefix":"10.1007","volume":"44","author":[{"given":"Fernando","family":"Barata","sequence":"first","affiliation":[]},{"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-7661","authenticated-orcid":false,"given":"Tiago Reis","family":"Marques","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9848-5832","authenticated-orcid":false,"given":"Jos\u00e9 Bravo","family":"Marques","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-0063","authenticated-orcid":false,"given":"Venceslau","family":"Hespanhol","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1083_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1083_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92\u20138. https:\/\/doi.org\/10.1056\/NEJMoa011954.","journal-title":"N Engl J Med"},{"issue":"7153","key":"1083_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136. https:\/\/doi.org\/10.1038\/nature05945.","journal-title":"Nature"},{"issue":"8","key":"1083_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou S-HI, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863\u201370. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1083_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3978\/j.issn.2218-6751.2013.03.1","volume":"2","author":"RP de la Bellacasa","year":"2013","unstructured":"de la Bellacasa RP, Karachaliou N, Estrada-Tejedor R, Teixid\u00f3 J, Costa C, Borrell JI, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013;2(2):72\u201386. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2013.03.1.","journal-title":"Transl Lung Cancer Res."},{"issue":"8","key":"1083_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","volume":"31","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105\u201311. https:\/\/doi.org\/10.1200\/JCO.2012.44.5353.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1083_CR8","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963\u201371. https:\/\/doi.org\/10.1056\/NEJMoa1406766.","journal-title":"N Engl J Med"},{"issue":"23","key":"1083_CR9","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1408440.","journal-title":"N Engl J Med"},{"issue":"13","key":"1083_CR10","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","volume":"16","author":"I Zhang","year":"2015","unstructured":"Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16(13):e510\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(15)00013-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1083_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.neo.2016.02.001","volume":"18","author":"X Dong","year":"2016","unstructured":"Dong X, Fernandez-Salas E, Li E, Wang S. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells. Neoplasia. 2016;18(3):162\u201371. https:\/\/doi.org\/10.1016\/j.neo.2016.02.001.","journal-title":"Neoplasia"},{"issue":"10","key":"1083_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0596.","journal-title":"Cancer Discov"},{"key":"1083_CR13","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(17)30680-0.","journal-title":"Lancet Oncol"},{"key":"1083_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-vinay S, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2017;18:1590\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30655-2.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1083_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer\u202f: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1083_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","volume":"15","author":"TM Bauer","year":"2020","unstructured":"Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol. 2020;15(1):55\u201365. https:\/\/doi.org\/10.1007\/s11523-020-00702-4.","journal-title":"Target Oncol"},{"issue":"8","key":"1083_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103\u201310. https:\/\/doi.org\/10.1634\/theoncologist.2018-0380.","journal-title":"Oncologist"},{"key":"1083_CR18","unstructured":"European Medicines Agency. Lorviqua: EPAR\u2014product information. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lorviqua-epar-product-information_en.pdf. Accessed 23 Mar 2021."},{"key":"1083_CR19","unstructured":"European Medicines Agency. Lorviqua: EPAR\u2014risk management plan summary. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/lorviqua-epar-risk-management-plan-summary_en.pdf. Accessed 26 Mar 2021."},{"issue":"2","key":"1083_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s12325-019-01198-9","volume":"37","author":"J Chen","year":"2020","unstructured":"Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, et al. The effect of rifampin on the pharmacokinetics and safety of Lorlatinib: results of a phase one, open-label, crossover study in healthy participants. Adv Ther. 2020;37(2):745\u201358. https:\/\/doi.org\/10.1007\/s12325-019-01198-9.","journal-title":"Adv Ther"},{"key":"1083_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejpb.2019.01.016","volume":"136","author":"W Li","year":"2019","unstructured":"Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK\/ROS1 inhibitor lorlatinib. Eur J Pharm Biopharm. 2019;136:120\u201330. https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.016.","journal-title":"Eur J Pharm Biopharm"},{"key":"1083_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10637-019-00872-7","volume":"38","author":"M Patel","year":"2020","unstructured":"Patel M, Chen J, McGrory S, Gorman MO, Ginman K, Pithavala YK. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. Invest New Drugs. 2020;38:131\u20139.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1083_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"2","key":"1083_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola V-P, Mebazaa A, Brunner-La Rocca H-P, Martens P, et al. The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369.","journal-title":"Eur J Heart Fail"},{"key":"1083_CR25","volume-title":"Textbook of Cardiovascular Medicine","author":"D Wolbrette","year":"2007","unstructured":"Wolbrette D, Naccarelli G. Textbook of Cardiovascular Medicine. 3rd ed. Oxford: Oxford University Press; 2007.","edition":"3"},{"key":"1083_CR26","doi-asserted-by":"publisher","first-page":"102969","DOI":"10.1016\/j.critrevonc.2020.102969","volume":"151","author":"M Nagasaka","year":"2020","unstructured":"Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou S-HI. A user\u2019s guide to lorlatinib. Crit Rev Oncol Hematol. 2020;151:102969. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102969.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1083_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162\u201374. https:\/\/doi.org\/10.1093\/neuonc\/now241.","journal-title":"Neuro Oncol"},{"key":"1083_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/B978-0-12-811161-1.00007-4","volume":"149","author":"WB Pope","year":"2018","unstructured":"Pope WB, Angeles L, States U. Brain metastases: neuroimaging. Handb Clin Neurol. 2018;149:89\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00007-4.","journal-title":"Handb Clin Neurol"},{"key":"1083_CR29","volume-title":"Brain tumours (primary) and brain metastases in adults: NICE guideline [NG99]","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in adults: NICE guideline [NG99]. London: National Institute for Health and Care Excellence; 2018."},{"issue":"2","key":"1083_CR30","first-page":"99","volume":"28","author":"TI Prior","year":"2003","unstructured":"Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28(2):99\u2013112.","journal-title":"J Psychiatry Neurosci"},{"key":"1083_CR31","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): non-small cell lung cancer. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 23 Mar 2021."},{"key":"1083_CR32","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): central nervous system cancers. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf. Accessed 23 Mar 2021."},{"issue":"2","key":"1083_CR33","first-page":"1054","volume":"3","author":"G Ayano","year":"2016","unstructured":"Ayano G. Psychotropic medications metabolized by cytochromes P450 (CYP) 3A4 enzyme and relevant drug interactions: review of articles. Austin J Psychiatry Behav Sci. 2016;3(2):1054.","journal-title":"Austin J Psychiatry Behav Sci."},{"issue":"1","key":"1083_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41\u201357. https:\/\/doi.org\/10.2165\/00003088-200038010-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1083_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/NDT.S157708","volume":"14","author":"Y Low","year":"2018","unstructured":"Low Y, Setia S, Lima G. Drug\u2013drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567\u201380. https:\/\/doi.org\/10.2147\/NDT.S157708.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"1083_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","volume":"90","author":"JC Watson","year":"2015","unstructured":"Watson JC, Dyck PJB. Peripheral neuropathy: a practical approach to diagnosis and symptom management. Mayo Clin Proc. 2015;90(7):940\u201351. https:\/\/doi.org\/10.1016\/j.mayocp.2015.05.004.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1083_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","volume":"14","author":"M Chincholkar","year":"2020","unstructured":"Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104\u201314. https:\/\/doi.org\/10.1177\/2049463720912496.","journal-title":"Br J Pain"},{"issue":"1491","key":"1083_CR38","first-page":"101","volume":"132","author":"P McQuoid","year":"2019","unstructured":"McQuoid P. Switching from gabapentin to pregabalin. N Z Med J. 2019;132(1491):101\u20133.","journal-title":"N Z Med J"},{"issue":"10","key":"1083_CR39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661\u20139. https:\/\/doi.org\/10.2165\/11536200-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1083_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MJT.0b013e318250f80e","volume":"20","author":"HN Bockbrader","year":"2013","unstructured":"Bockbrader HN, Budhwani MN, Wesche DL. Gabapentin to pregabalin therapy transition: a pharmacokinetic simulation. Am J Ther. 2013;20(1):32\u20136. https:\/\/doi.org\/10.1097\/MJT.0b013e318250f80e.","journal-title":"Am J Ther"},{"issue":"7","key":"1083_CR41","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1526-4637.2011.01162.x","volume":"12","author":"M Ifuku","year":"2011","unstructured":"Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med. 2011;12(7):1112\u20136. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01162.x.","journal-title":"Pain Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01083-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T15:36:11Z","timestamp":1626276971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01083-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01083-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"18 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"FB received speaker\u2019s fees and honoraria from AstraZeneca, Boeringher Ingelheim, Bristol Myers Squibb, MSD Oncology, Pfizer, Roche and Takeda for participating in advisory boards. CA has received honoraria from Pfizer for consulting. TRM has conducted research funded by the Medical Research Council (UK), King\u00b4s Health Partners and King\u2019s College London, and has received honoraria for speaking and chairing engagements from Lundbeck, Janssen, Astellas and Pfizer. JBM and VH received honoraria from Pfizer for participating in advisory boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors approved the publication of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable as no new data were created or analysed in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"FB devised and coordinated the project. All authors participated in the advisory board in which the recommendations were discussed, and contributed to the writing of the manuscript. All authors also read and approved the final version of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}